Esophageal cancer

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

Researchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

This early-phase trial tests an oral drug called R01 in people with advanced squamous cell lung cancer, gastric cancer, or esophageal cancer that has progressed after standard treatment. The study aims to find the safest dose and check whether R01 can shrink tumors. Participants …

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This trial tests a cell therapy called DC-CTL, made from a patient's own immune cells, combined with standard anti-tumor treatment. The goal is to see if this approach is safe and may help control solid tumors such as colorectal, esophageal, lung, liver, and breast cancer. About …

This trial tests whether high-flow nasal cannula (HFNC) oxygen can reduce the risk of hypoxemia, or low blood oxygen, during sedated gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD). COPD patients often have low oxygen reserves, making them…

This early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …

This trial tests whether using a dye to identify and remove only the sentinel lymph nodes (the first nodes cancer might spread to) during esophageal cancer surgery is as effective as removing all nearby lymph nodes. The study includes 200 adults with early-stage esophageal squamo…

This study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…

This phase 2 trial is testing whether giving a combination of adebrelimab (an immunotherapy), thymalfasin (an immune booster), and chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The study will enroll about 31 adults…

This study tests whether people with certain gastrointestinal cancers—like stomach, esophageal, or colorectal—can safely skip radical surgery after responding well to precision therapies such as immunotherapy or targeted drugs. Participants with specific molecular markers will be…

This phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …

This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without addit…

This phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…

This study tests whether a dye called indocyanine green (ICG), given before surgery, can help surgeons see and protect the recurrent laryngeal nerve during esophageal cancer removal. About 144 adults with esophageal cancer will be randomly assigned to get the dye or standard surg…

This trial will test a new robot system designed to help surgeons perform laparoscopic surgery from a remote location. The study includes 98 adults with cancers like colorectal, esophageal, liver, or cervical cancer who need surgery. The main goal is to see how often the surgery …

This study tests a new surgical technique for people with esophageal cancer. The method uses a special dye to check blood flow and wraps the surgical connection with a piece of belly tissue to prevent leaks. About 73 adults will receive this procedure to see if it lowers the risk…

This study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be …

This study looks at adding a precise, high-dose radiation treatment called SBRT to standard chemotherapy and immunotherapy for people with esophageal cancer that has spread to a few other spots in the body. The goal is to see if this combination can help control the cancer longer…

This study tests a new drug called QL1706 combined with chemotherapy for people with a type of esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough so that surgery can be done successfully. 24 adults with this cancer will receive the drug …

This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the comb…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study asks whether two PET/CT scans taken before treatment can predict how well patients with esophageal cancer respond to immunotherapy plus chemotherapy given before surgery. Adults with stage II to IVA esophageal squamous cell carcinoma will receive both scans, and those …

This study tests whether a special dye, called indocyanine green, can help surgeons find cancer that has spread to nearby lymph nodes during esophageal cancer surgery. About 144 adults with esophageal cancer will take part. If the dye works well, it may allow doctors to remove fe…

This study will test whether an artificial intelligence system can detect minimal residual disease—tiny amounts of cancer left after surgery—and predict recurrence in 700 people with rectal cancer. The AI combines blood tests, genetic data, and scans to create a more complete pic…

This study tests whether a product made from spirulina (a type of algae) can prevent severe throat pain caused by radiation therapy in people with esophageal cancer. About 70 patients will receive either the spirulina derivative or a placebo during their radiation treatments. The…

This study tests a digital tool called RECapp that helps patients recover after surgery for esophageal or stomach cancer. The app lets patients track symptoms, get personalized self-care advice, and know when to contact their healthcare team. 250 adults in Sweden will use the app…

This early-stage trial tests a new robotic surgical method for esophageal cancer that avoids cuts between the ribs, which may cause less chest pain and faster recovery. About 31 adults with stage I to III esophageal cancer will be randomly assigned to either the new approach or s…

This study tests whether the MetaNeb system, a device that delivers breathing treatments, can prevent or treat lung collapse (atelectasis) in 178 adults recovering from esophageal cancer surgery. Participants will be randomly assigned to receive either MetaNeb therapy or standard…

This trial investigates how the body handles larotinib, an experimental cancer drug, in people with mild or moderate liver impairment compared to healthy volunteers. Participants receive a single oral dose, and researchers measure drug levels in the blood over time. The goal is t…

This study will check if certain immune cells, called precursor exhausted T cells, found in cancer-free lymph nodes can predict whether esophageal cancer completely disappears after immunotherapy. Researchers will study 88 patients before surgery to see if these cells are better …

This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes …

This early-phase study tests a new imaging method to see if immunotherapy targets (PD-1 and PD-L1 proteins) are present in esophageal cancer. About 15 participants will receive two fluorescent tracers before a routine endoscopic exam. The goal is to find out if this 'fluorescence…

This study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…